Immatics (IMTX) Change in Accured Expenses (2019 - 2026)
Immatics (IMTX) posted Change in Accured Expenses of -$34.4 million for Q1 2024, down 303.35% sequentially from $16.9 million in Q4 2023, and down 311.37% YoY from $16.3 million in Q2 2023.
Analysis
Immatics (IMTX) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Immatics has reported Change in Accured Expenses for 6 years, with the latest figure at -$34.4 million in Q1 2024.
- Quarterly Change in Accured Expenses fell 311.37% year-over-year to -$34.4 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was -$26.0 million (down 433.43% YoY) and the FY2025 annual result came in at -$42.5 million, up 73.78% from the prior year.
- Change in Accured Expenses fell to -$34.4 million in Q1 2024 per IMTX's latest filing, from $16.9 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $68.4 million in Q2 2022 and troughed at -$39.4 million in Q4 2022.
- A 5-year average of -$2.3 million and a median of -$7.4 million in 2020 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 1304.44% in 2022, then slumped 311.37% in 2024.
- Over 5 years, Change in Accured Expenses stood at -$8.8 million in 2020, then tumbled by 128.77% to -$20.1 million in 2021, then plunged by 96.28% to -$39.4 million in 2022, then surged by 142.94% to $16.9 million in 2023, then slumped by 303.35% to -$34.4 million in 2024.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$34.4 million, $16.9 million, and -$6.3 million for Q1 2024, Q4 2023, and Q3 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -609,077.61 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -609,077.61 |
| Mar 31, 2026 | 12.18 Mn |
| Dec 31, 2025 | -44.63 Mn |
| Sep 30, 2025 | 19.01 Mn |
| Jun 30, 2025 | 551,264.37 |
| Mar 31, 2025 | -16.85 Mn |
| Dec 31, 2024 | -160.71 Mn |
| Sep 30, 2024 | 256,983.36 |
| Jun 30, 2024 | 243,376.59 |
| Mar 31, 2024 | 210,754.18 |
| Dec 31, 2023 | 91.86 Mn |
| Sep 30, 2023 | 238,401.31 |
| Jun 30, 2023 | 8.92 Mn |
| Mar 31, 2023 | -8.36 Mn |
| Dec 31, 2022 | -39.41 Mn |
| Sep 30, 2022 | -12.85 Mn |
| Jun 30, 2022 | 68.43 Mn |
| Mar 31, 2022 | 36.81 Mn |
| Dec 31, 2021 | -20.08 Mn |
| Sep 30, 2021 | -3.38 Mn |